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Cardiodilatins/atrial natriuretic peptides (CDD/ANP) exhibit a common amino acid sequence: Argr”‘- 
Arg 102-Ser’03-Ser1w. Cyclic AMP-dep endent phosphorylation of Ser lo4 of atria1 peptides with [y-32P]ATP 
enables rapid identification of cardiac hormones. The biological activity of in vitro phosphorylated cardio- 
dilatin (CDD-28/a-hANP) is dramatically altered compared to the unphosphorylated peptide: the vaso- 
relaxant effect of cardiodilatin 28 is inhibited upon phosphorylation. 
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1. INTRODUCTION 
The role of a particular family of atria1 peptides 
as regulators of blood pressure [ 1,2] by stimulation 
of natriuresis, diuresis and vascular smooth muscle 
relaxation [3-61 has been generally acknowledged 
for several years. These peptides are designated 
atria1 natriuretic factor (ANF) or cardiodilatin 
(CDD) [5]. The peptides are derived from a com- 
mon precursor whose amino acid sequence is well 
established [6]. The largest fraction of peptides ex- 
tracted from porcine atria using the method of 
Mutt [7], which includes heating, is cardiodilatin 
126 (CDD-126). As a side fraction, CDD-88 was 
extracted. CDD-88 is bioactive [8] and comprises 
amino acids 38-126 of CDD-126. The final 28 
amino acids of these peptides correspond to 
human wANP [9]. Both bioactive peptides 
(CDD-88, CDD-28) show a common amino acid 
sequence: Arg101-Arg102-Ser’03-Ser104. Phosphory- 
lation of a serine residue by CAMP-dependent pro- 
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tein kinase (cPK) requires a recognition sequence 
of Arg-Arg-X-Ser [lo]. It has recently been 
reported [ll] that two synthetic forms of CDD 
consisting of amino acids Gly96-Tyr126 and 
Arg’01-Tyr126 are phosphorylated by CAMP- 
dependent protein kinase at Serlo4. The low Km 
value of the longer peptide of 0.5 PM demonstrates 
extraordinary substrate susceptibility. Furtner- 
more, it was demonstrated by the same authors 
that the Na+/K+/Cl- co-transport in cultured 
vascular smooth muscle cells was enhanced atter 
phosphorylation of the peptide Arg’“‘-Tyr126. 
Because of the vasorelaxant properties of CDD-28 
and CDD-88 we investigated the effects of CAMP- 
dependent phosphorylation of both peptides on 
smooth muscle relaxation. The observation that 
the peptides of the atria1 natriuretic peptide family 
are phosphorylated CAMP-dependently offers the 
possibility for rapid detection of these peptides in 
crude tissue extracts, serum or urine, thus 
facilitating their preparation. 
2. MATERIALS AND METHODS 
Aortae were prepared from New Zealand rab- 
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bits. The tension was measured isometrically in an 
organ bath on helical strips by standard methods 
[12]. Incubation of the strips was performed in 
physiological salt solution as in [5]. Initially, strips 
were pretreated with 10e6 M norepinephrine 
followed by complete relaxation. For the assay 
another contraction was elicited by lo-’ M 
norepinephrine. When constant force levels had 
been obtained, peptides were added. Preparation 
of CAMP-dependent protein kinase (EC 2.7.1.37) 
from bovine cardiac muscle was as described 
earlier [ 131. Isolation of CDD-88 from bovine atria 
[ 141 was carried out in our laboratory; CDD-28 (a- 
hANP) was a gift from Bissendorf Peptides Co. 
For the phosphorylation reaction, peptides were 
incubated in Eppendorff tubes at 30°C in a solu- 
tion containing 100 mM Mops buffer (pH 6.8), 
10 mM Mg acetate and 12-13 pug catalytic subunit 
of CAMP-dependent protein kinase (100 ~1 reac- 
tion volume). The reaction was started by the addi- 
tion of 1Oyl of 2 mM ATP, unless otherwise 
stated. In the case of radioactive labelling 
[y-32P]ATP from NEN was included (0.5 mCi/ 
pmol ATP). Controls were treated identically ex- 
cept that no catalytic subunit was present. The use 
of plastic tubes was necessary because of undesired 
peptide absorption to glass. Aliquots were 
separated by high-performance liquid chroma- 
tography on a reverse-phase column (TSK-ODS 
120T). The column was developed by using a linear 
gradient of acetonitrile (5 - 80%) containing 0.01 
N HCI using a device from Waters Associates. 
Absorption was measured at 210 nm. Fractions of 
1.5 ml were eluted and aliquots (0.5 ml) were 
counted in a liquid scintillation counter with 2 ml 
water. 
3. RESULTS AND DISCUSSION 
Cyclic AMP-dependent phosphorylation of 
CDD-28 and CDD-88 was tested by assaying 91(g 
CDD-28 and 13 pg CDD-88 phosphorylated with 
12 pg cPK as described in section 2. After 15 min 
reaction at 3O”C, 70 ~1 of the reaction volume was 
applied onto a TSK-ODS 120T column. The col- 
umn was eluted with a linear gradient of 
acetonitrile (5-80%) containing 0.01 N HCl. A 
typical elution pattern of a phosphorylated mix- 
ture of CDD-28 and CDD-88 is demonstrated in 
fig.lA (ATP is not retained and elutes in front). 
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CDD-28 was eluted at 42% acetonitrile followed 
by elution of CDD-88 (48% acetonitrile). Both 
peaks contained incorporated radioactivity in- 
dicating phosphorylation of a serine residue by the 
catalytic subunit of CAMP-dependent protein 
kinase (cPK). The specific phosphorylation of 
atria1 natriuretic peptides provides a useful tool for 
rapid identification of the peptide hormones as 
may be observed in fig.lB. Here, an aliquot of a 
crude extract from bovine atria (15 pg protein) was 
phosphorylated in the presence of 13 pg cPK for 
20 min and 80~1 of the reaction volume was ap- 
plied onto the column. As can be seen in fig.lB, a 
peak of radioactivity is eluted at 48% acetonitrile 
indicating the presence of CDD-88. 
The bioactivity of atria1 natriuretic peptide hor- 
mones is identified by means of biotests with 
vascular smooth muscles. In this assay the bioac- 
tive substances exhibit vasorelaxation. The 
vasorelaxant effect of unphosphorylated and 
phosphorylated CDD-28 and CDD-88 was tested 
using rabbit aorta strips in an organ bath solution. 
After contraction, when constant force levels had 
been achieved, peptides were added at a final con- 
centration of 0.3-0.6 x 10m9 M. A typical experi- 
ment showing the effects of unphosphorylated and 
phosphorylated CDD-28 on contracted aortic mus- 
cle strips is depicted in fig.2. In comparison to 
phosphorylated CDD-28 (broken line) the applica- 
tion (arrow) of unphosphorylated CDD-28 (con- 
tinuous line) causes pronounced relaxation; thus 
relaxation of vascular smooth muscle is strongly 
inhibited upon application of phosphorylated 
CDD-28. The inset in fig.2 summarizes a number 
of experiments with unphosphorylated and 
phosphorylated CDD-28 and CDD-88 performed 
with different smooth muscle preparations. As a 
measure of the bioactivity the rate of tension 
decline (force decay between 2 and 10 min after 
application of the peptide) was plotted vs the 
logarithm of the time (100% tension prior to ap- 
plication of peptides). The rate of relaxation was 
calculated from the slopes. The slopes are not true 
rate constants but only estimates of the relative 
relaxation per time period. Application of 0.3-0.6 
x 10e9 M phosphorylated CDD-28 strongly 
depresses relaxation by a factor of about four com- 
pared to the unphosphorylated peptide. Relaxation 
caused by 0.3-0.6 x lob9 M unphosphorylated 
CDD-88 is less compared to that observed with un- 
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Fig. 1, Elution pattern of phosphorylated CDD-28 and CDD-88 (A) and phosphorylated crude bovine atria1 extract (B). 
Cyclic AMP-dependent phosphorylated aliquots of CDD-28 and CDD-88 were separated by reverse-phase HPLC on 
a TSK-ODS-120T column (300 x 7.8 mm i.d.). Solvent system: a, 0.01 M HCl; b, 0.01 M HCl in 80% aqueous 
acetonitrile; flow rate, 1.5 ml/min. The gradient is shown by the continuous line. Absorbance (-) was measured at 
210 nm (0.1 absorbance unit range). For detection of radioactivity (M) 0.5 ml aliquots per fraction were counted. 
phosphorylated CDD-28. Phosphorylation of Studies on primary cultures of neonatal rat car- 
CDD-88, however, has no significant effect on the diocytes [ 161 demonstrate that CAMP-dependent 
relaxation rate. This result is not unexpected, as phosphorylation of Serlo4 in the 126 amino acid 
CDD-88 is extracted from atria1 tissue and to our precursor (proANP) occurs to an insignificant ex- 
knowledge so far, does not represent a circulating tent. Thus, it seems unlikely that the physiological 
peptide [15]. mechanism of CAMP-dependent phosphorylation 
Fig.2. Effect of CAMP-dependent phosphorylation of 
CDD-28 and CDD-88 on vascular smooth muscle 
relaxation. Rabbit aortic muscle strips were 
precontracted by lo-’ M norepinephrine. Upon plateau 
force levels being achieved, peptides were added (arrow) 
at a final concentration of 0.3-0.6 x 10m9 M 
(unphosphorylated CDD-28, continuous line; phos- 
phorylated CDD-28, broken line). The inset summarises 
a number of experiments showing the estimates of the 
rate of relaxation + SE for unphosphorylated (open 
bars) and phosphorylated (stippled bars) CDD-28 and 
CDD-88, respectively. In order to ensure complete 
phosphorylation of CDD-28 and CDD-88 the 
concentration of co-substrate in the reaction volume was 
doubled and the incubation time was prolonged to 
40 min. TIME (Min) 
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controls storage or excretion of the peptide hor- 
mone. However, CAMP-dependent phosphoryla- 
tion may be involved in regulation of the biological 
activity upon secretion. It has been reported that 
the effect of CDD-28/a-hANP on vascular smooth 
muscles exhibits regional selectivity [ 17,181. The 
heterogeneity in vasorelaxation seems not to arise 
solely as a result of differences in the regional 
distribution of high-affinity receptors for 
CDD/ANP. In addition, differences in the 
distribution of particulate guanylate cyclase may 
influence the vasorelaxant activity ([19] and 
references cited therein). Modification of the hor- 
mone itself appears to determine whether vessels 
exhibit relaxation to CDD/ANP. Our observations 
show decreased smooth muscle relaxation after 
CAMP-dependent phosphorylation of CDD-28/a- 
hANP. Thus, one may suggest hat the expression 
of a specific peptide activity on a target tissue may 
be controlled by a fine tuning mediated by a 
phosphorylation-dependent modification step of 
the hormone. 
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